Kaleido Invested Capital Average Trend from 2010 to 2021

KLDO -  USA Stock  

USD 4.94  0.27  5.18%

Kaleido Biosciences Invested Capital Average yearly trend continues to be quite stable with very little volatility. The value of Invested Capital Average is projected to decrease to about 20 M. From the period between 2010 and 2021, Kaleido Biosciences, Invested Capital Average regression line of its data series had standard deviation of 3,339,292 and standard deviation of  3,339,292. Research and Development Expense is expected to rise to about 56 M this year, although the value of Consolidated Income will most likely fall to (88.1 M).

Kaleido Historical Trends 

 
Refresh
Check Kaleido Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kaleido main balance sheet or income statement drivers, such as Gross Profit of 872.4 K, Interest Expense of 2.2 M or Operating Expenses of 78.8 M, as well as many exotic indicators such as Asset Turnover of 0.0125, Book Value per Share of 0.66 or Current Ratio of 4.08. Kaleido financial statements analysis is a perfect complement when working with Kaleido Biosciences Valuation or Volatility modules. It can also supplement various Kaleido Biosciences Technical models. Please see the analysis of Kaleido Biosciences Correlation against competitors.

Kaleido Invested Capital Average Breakdown

Showing smoothed Invested Capital Average of Kaleido Biosciences with missing and latest data points interpolated. Average invested capital value for the period used in the calculation of [ROIC]; and derived from [InvCap]. Invested capital is an input into the calculation of [ROIC]; and is calculated as: Total Debt plus Total Assets minus [Intangibles] minus Cash and Equivalents minus Current Liabilities. Please note this calculation method is subject to change.Kaleido Biosciences' Invested Capital Average historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kaleido Biosciences' overall financial position and show how it may be relating to other accounts over time.
Invested Capital Average10 Years Trend
Increasing
Slightly volatile
 Invested Capital Average 
Share
      Timeline 

Kaleido Invested Capital Average Regression Statistics

Arithmetic Mean 13,428,066
Geometric Mean 13,121,970
Coefficient Of Variation 24.87
Mean Deviation 2,430,850
Median 11,807,500
Standard Deviation 3,339,292
Range 9,073,250
R-Value 0.71
R-Squared 0.50
Significance 0.010273
Slope 653,973

Kaleido Invested Capital Average History

201914 M
202020.9 M
202120 M

About Kaleido Biosciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Kaleido Biosciences income statement, its balance sheet, and the statement of cash flows. Kaleido Biosciences investors use historical funamental indicators, such as Kaleido Biosciences's Invested Capital Average, to determine how well the company is positioned to perform in the future. Although Kaleido Biosciences investors may use each financial statement separately, they are all related. The changes in Kaleido Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kaleido Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Kaleido Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Kaleido Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Invested Capital15.3 M16.4 M
Invested Capital Average20.9 M20 M
Market Capitalization327.4 M310.8 M
Working Capital32.1 M43.6 M
Average Assets71.6 M82.7 M
Average Equity35.3 M38.1 M
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kaleido Biosciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Diagnostics Now

   

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kaleido Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Kaleido Biosciences Correlation against competitors. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.